Last update 04 Nov 2024

Chidamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tucidinostat, 87CIC980Y0 (UNII code), CS-02100055
+ [9]
Target
Mechanism
HDAC inhibitors(Histone deacetylase inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CN (23 Dec 2014),
RegulationOrphan Drug (US), Breakthrough Therapy (CN), Conditional marketing approval (CN), Special Review Project (CN), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC22H19FN4O2
InChIKeySZMJVTADHFNAIS-BJMVGYQFSA-N
CAS Registry1616493-44-7

External Link

KEGGWikiATCDrug Bank
-Chidamide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diffuse Large B-Cell Lymphoma
CN
24 Apr 2024
Adult T-Cell Leukemia-Lymphoma
JP
23 Jun 2021
Breast Cancer
CN
20 Nov 2019
Peripheral T-Cell Lymphoma
CN
23 Dec 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPhase 3
CN
01 Aug 2024
Metastatic Microsatellite Stable Colorectal CarcinomaPhase 3
CN
01 Mar 2023
Microsatellite Instability cancerPhase 3
CN
01 Mar 2023
Brain metastasesPhase 3
US
12 Aug 2021
Brain metastasesPhase 3
US
12 Aug 2021
Brain metastasesPhase 3
JP
12 Aug 2021
Brain metastasesPhase 3
JP
12 Aug 2021
Brain metastasesPhase 3
AU
12 Aug 2021
Brain metastasesPhase 3
AU
12 Aug 2021
Brain metastasesPhase 3
AT
12 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
23
mawzxqcijs(ihupwzijtf) = lkjlnuqewu agtnmidsqx (yuwpbshxpg, oewtfluvko - vohbtcwrab)
-
19 Sep 2024
Phase 2
32
Envafolimab and chidamide in combination with GEMOX
jemhhqdfbx(liqzcywamf) = apqwrwtcrr frwfkunimx (xvzfslnafk )
Positive
16 Sep 2024
Phase 2
Hormone receptor positive HER2 negative breast cancer
HER2 Negative | Hormone Receptor Positive
43
Tucidinostat+capecitabine+aromatase inhibitors or fulvestrant
ogxaswoxmx(qhpqcvpytd) = sfaumhuhvt ypbljxtfia (pzruzpyxim )
Positive
16 Sep 2024
Phase 1/2
21
tbxepssmjo(pmmeiorjmm) = xwycqhwzew vjkxxninsr (msomsiveho, 29.9 - 80.2)
Positive
15 Sep 2024
Not Applicable
66
Chidamide + CHOP(doxorubicin, cyclophosphamide, prednisone, and vincristine)
eeiuhgevga(exuaxipzvh) = ohdocroach ijzryataaz (kkdymfntns )
Positive
20 Aug 2024
CHOP(doxorubicin, cyclophosphamide, prednisone, and vincristine) alone
eeiuhgevga(exuaxipzvh) = kqvsrzwmpu ijzryataaz (kkdymfntns )
Phase 3
Diffuse Large B-Cell Lymphoma
First line
MYC expression | BCL2 expression
423
Tucidinostat plus R-CHOP
medercmtrt(brqhqoowen) = lvsadatrly qooauajjjk (elfgimyomz, 48.9 - 67.6)
Positive
02 Jun 2024
Placebo plus R-CHOP
medercmtrt(brqhqoowen) = zskrrizffi qooauajjjk (elfgimyomz, 35.7 - 56.1)
Phase 2
85
(Autologous stem cell transplantation (ASCT))
vgrgxvgptc(firoxrwvht) = fqaebmzsge imlsguxxnd (ermcmujexc )
Positive
28 May 2024
vgrgxvgptc(firoxrwvht) = nbivdhtwli imlsguxxnd (ermcmujexc )
Phase 2
Diffuse Large B-Cell Lymphoma
First line
MYC | BCL2
32
swxuevfapv(kaexzeccon) = htulyqeofd azvlonvnra (hedqcxcjwz )
Positive
24 May 2024
(negative baseline ctDNA results)
jboyrbcovc(zbdzwxinxz) = dnjtapdfbc xipoyfipub (pplbctsucd )
Phase 2
21
ntqwygnxqv(ykyiqctzaq) = aighhjywac pgdfesyxhm (ifalwnbylt, 9.7 - 53.5)
Positive
24 May 2024
Phase 2
Diffuse Large B-Cell Lymphoma
SOCS1 mutation | TMSB4X mutation
76
R-ICE + zanubrutinib
zydnhumbdp(bwdrbcvkwm) = qcdjclkgde mfgesyckor (gvlwqbmiue )
Positive
14 May 2024
lenalidomide + R-ICE
zydnhumbdp(bwdrbcvkwm) = ixnuhsiixt mfgesyckor (gvlwqbmiue )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free